


RealRate

PHARMACEUTICAL 2020

PROCYON

PROCYON CORP Rank 29 of 362





PHARMACEUTICAL 2020



PROCYON CORP Rank 29 of 362

PROCYON

The relative strengths and weaknesses of PROCYON CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PROCYON CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 1,055% points. The greatest weakness of PROCYON CORP is the variable Other Expenses, reducing the Economic Capital Ratio by 300% points.

The company's Economic Capital Ratio, given in the ranking table, is 169%, being 472% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	1,594
Cost of Goods Sold	1,142
Intangible Assets	17
Liabilities, Current	376
Liabilities, Non-Current	0
Other Assets	336
Other Compr. Net Income	0
Other Expenses	1,606
Other Liabilities	0
Other Net Income	2.2
Property and Equipment	488
Research and Development	0
Revenues	4,191
Selling, General and Administrative Expense	1,418

Output Variable	Value in 1000 USD
Assets	2,435
Liabilities	376
Expenses	4,166
Stockholders Equity	2,059
Net Income	27
Comprehensive Net Income	27
Economic Capital Ratio	169%